JP2019501206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501206A5 JP2019501206A5 JP2018536151A JP2018536151A JP2019501206A5 JP 2019501206 A5 JP2019501206 A5 JP 2019501206A5 JP 2018536151 A JP2018536151 A JP 2018536151A JP 2018536151 A JP2018536151 A JP 2018536151A JP 2019501206 A5 JP2019501206 A5 JP 2019501206A5
- Authority
- JP
- Japan
- Prior art keywords
- glycine
- composition
- composition according
- cancer
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 36
- 230000003818 metabolic dysfunction Effects 0.000 claims description 34
- 108010076365 Adiponectin Proteins 0.000 claims description 33
- 102000011690 Adiponectin Human genes 0.000 claims description 33
- 102000016267 Leptin Human genes 0.000 claims description 32
- 108010092277 Leptin Proteins 0.000 claims description 32
- 229940039781 leptin Drugs 0.000 claims description 32
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 21
- 102000004877 Insulin Human genes 0.000 claims description 18
- 108090001061 Insulin Proteins 0.000 claims description 18
- 229940125396 insulin Drugs 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 16
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 11
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 11
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
- 201000010881 cervical cancer Diseases 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 206010014733 Endometrial cancer Diseases 0.000 claims description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 10
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 10
- 208000037976 chronic inflammation Diseases 0.000 claims description 10
- 230000006020 chronic inflammation Effects 0.000 claims description 10
- 201000010175 gallbladder cancer Diseases 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000004930 Fatty Liver Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 66
- 239000000203 mixture Substances 0.000 claims 47
- 239000004471 Glycine Substances 0.000 claims 33
- 229960002449 glycine Drugs 0.000 claims 33
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 15
- 229960003136 leucine Drugs 0.000 claims 15
- 235000005772 leucine Nutrition 0.000 claims 15
- 229960005190 phenylalanine Drugs 0.000 claims 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 15
- 235000008729 phenylalanine Nutrition 0.000 claims 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 13
- 229960004295 valine Drugs 0.000 claims 13
- 239000004474 valine Substances 0.000 claims 13
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 9
- 229960001230 asparagine Drugs 0.000 claims 9
- 235000009582 asparagine Nutrition 0.000 claims 9
- 229930182817 methionine Natural products 0.000 claims 9
- 229960004452 methionine Drugs 0.000 claims 9
- 235000006109 methionine Nutrition 0.000 claims 9
- 229960004799 tryptophan Drugs 0.000 claims 9
- 229960004441 tyrosine Drugs 0.000 claims 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 8
- 229960003767 alanine Drugs 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 7
- 239000004473 Threonine Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 7
- 229960002743 glutamine Drugs 0.000 claims 7
- 235000004554 glutamine Nutrition 0.000 claims 7
- 229960000310 isoleucine Drugs 0.000 claims 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 7
- 235000014705 isoleucine Nutrition 0.000 claims 7
- 229960001153 serine Drugs 0.000 claims 7
- 229960002898 threonine Drugs 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 5
- 229960003121 arginine Drugs 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 229960005261 aspartic acid Drugs 0.000 claims 5
- 235000003704 aspartic acid Nutrition 0.000 claims 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 5
- 229960002433 cysteine Drugs 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 229960002989 glutamic acid Drugs 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- 229960002885 histidine Drugs 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 229960003646 lysine Drugs 0.000 claims 5
- 229960002429 proline Drugs 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 235000013477 citrulline Nutrition 0.000 claims 2
- 229960002173 citrulline Drugs 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- -1 2-hydroxypropyl group Chemical group 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000005333 aroyloxy group Chemical group 0.000 claims 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 101150029707 ERBB2 gene Proteins 0.000 description 8
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical class C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 0 C*(C)**C(N(C)*)=O Chemical compound C*(C)**C(N(C)*)=O 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022016251A JP7640481B2 (ja) | 2016-01-11 | 2022-02-04 | 代謝機能不全によって引き起こされる腫瘍の治療 |
| JP2025025705A JP2025071236A (ja) | 2016-01-11 | 2025-02-20 | 代謝機能不全によって引き起こされる腫瘍の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277293P | 2016-01-11 | 2016-01-11 | |
| US62/277,293 | 2016-01-11 | ||
| US201662393929P | 2016-09-13 | 2016-09-13 | |
| US62/393,929 | 2016-09-13 | ||
| US201662395446P | 2016-09-16 | 2016-09-16 | |
| US62/395,446 | 2016-09-16 | ||
| PCT/US2017/012968 WO2017123603A1 (en) | 2016-01-11 | 2017-01-11 | Treatment for tumors driven by metabolic dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022016251A Division JP7640481B2 (ja) | 2016-01-11 | 2022-02-04 | 代謝機能不全によって引き起こされる腫瘍の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501206A JP2019501206A (ja) | 2019-01-17 |
| JP2019501206A5 true JP2019501206A5 (cg-RX-API-DMAC7.html) | 2020-02-20 |
| JP7022066B2 JP7022066B2 (ja) | 2022-02-17 |
Family
ID=57882196
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536151A Active JP7022066B2 (ja) | 2016-01-11 | 2017-01-11 | 代謝機能不全によって引き起こされる腫瘍の治療 |
| JP2022016251A Active JP7640481B2 (ja) | 2016-01-11 | 2022-02-04 | 代謝機能不全によって引き起こされる腫瘍の治療 |
| JP2025025705A Pending JP2025071236A (ja) | 2016-01-11 | 2025-02-20 | 代謝機能不全によって引き起こされる腫瘍の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022016251A Active JP7640481B2 (ja) | 2016-01-11 | 2022-02-04 | 代謝機能不全によって引き起こされる腫瘍の治療 |
| JP2025025705A Pending JP2025071236A (ja) | 2016-01-11 | 2025-02-20 | 代謝機能不全によって引き起こされる腫瘍の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10646463B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3402529A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7022066B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180100663A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114225045B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017206718B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3008960C (cg-RX-API-DMAC7.html) |
| MX (2) | MX2018008321A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017123603A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| ES2749746T3 (es) | 2013-04-10 | 2020-03-23 | Syndevrx Inc | Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad |
| US9969722B2 (en) | 2015-12-10 | 2018-05-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CN114225045B (zh) | 2016-01-11 | 2025-09-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
| SMT202200173T1 (it) | 2016-06-01 | 2022-05-12 | Athira Pharma Inc | Composti |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| AU2019366819C1 (en) * | 2018-10-26 | 2025-12-18 | Syndevrx Inc. | Biomarkers of MetAP2 inhibitors and applications thereof |
| CN112915210B (zh) * | 2019-12-06 | 2024-08-20 | 重庆阿普格雷生物科技有限公司 | 一种聚乙二醇偶联药物、其制备方法及应用 |
| CN116887836A (zh) * | 2020-11-11 | 2023-10-13 | 辛德弗雷克斯公司 | 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合 |
| KR20230117574A (ko) * | 2020-11-11 | 2023-08-08 | 신데브알엑스, 인크. | 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합 |
| AU2023322022A1 (en) * | 2022-08-10 | 2025-02-27 | Syndevrx, Inc. | Metap2 inhibitors for the treatment of pulmonary fibrosis |
| WO2024107996A1 (en) * | 2022-11-16 | 2024-05-23 | Syndevrx, Inc. | Metap2 inhibitors for the treatment of prostate cancer |
| CN119932197B (zh) * | 2025-04-09 | 2025-06-13 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| ES2224465T3 (es) | 1997-10-31 | 2005-03-01 | Children's Medical Center Corporation | Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado. |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
| SK16282000A3 (sk) | 1998-05-01 | 2001-05-10 | Abbott Laboratories | Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| EP1080732A4 (en) | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| HK1042438A1 (zh) | 1998-10-30 | 2002-08-16 | 第一制药株式会社 | Dds化合物及其测定方法 |
| EP1222217B1 (en) | 1999-09-08 | 2005-06-15 | Polytherics Limited | Uniform molecular weight polymers |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| US20040005641A1 (en) | 2002-02-15 | 2004-01-08 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| US7332523B2 (en) | 2002-04-11 | 2008-02-19 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| WO2009003110A2 (en) | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| AU2008331516B2 (en) | 2007-11-28 | 2014-01-09 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| CN101896177A (zh) | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| CN102105156B (zh) | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| CN102791699B (zh) * | 2010-01-08 | 2016-04-06 | 扎夫根公司 | 烟曲霉醇型化合物和其制造和使用方法 |
| US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
| WO2011150088A1 (en) | 2010-05-25 | 2011-12-01 | SynDevRX | Optimized drug conjugates |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| SMT201900190T1 (it) | 2010-11-12 | 2019-05-10 | Pharma Mar Sa | Multiterapia con un inibitore mitotico |
| MX342257B (es) | 2011-03-08 | 2016-09-21 | Zafgen Inc | Derivados y análogos de oxaspiro [2.5] octano. |
| ES2749746T3 (es) | 2013-04-10 | 2020-03-23 | Syndevrx Inc | Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad |
| HRP20211879T1 (hr) | 2013-08-14 | 2022-03-04 | Novartis Ag | Kombinirana terapija za liječenje raka |
| US9969722B2 (en) | 2015-12-10 | 2018-05-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CN114225045B (zh) | 2016-01-11 | 2025-09-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
| WO2018027084A2 (en) | 2016-08-03 | 2018-02-08 | Remd Biotherapeutics, Inc. | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer |
| AU2019366819C1 (en) | 2018-10-26 | 2025-12-18 | Syndevrx Inc. | Biomarkers of MetAP2 inhibitors and applications thereof |
-
2017
- 2017-01-11 CN CN202111316615.1A patent/CN114225045B/zh active Active
- 2017-01-11 WO PCT/US2017/012968 patent/WO2017123603A1/en not_active Ceased
- 2017-01-11 KR KR1020187022956A patent/KR20180100663A/ko active Pending
- 2017-01-11 MX MX2018008321A patent/MX2018008321A/es unknown
- 2017-01-11 US US15/403,675 patent/US10646463B2/en active Active
- 2017-01-11 JP JP2018536151A patent/JP7022066B2/ja active Active
- 2017-01-11 CA CA3008960A patent/CA3008960C/en active Active
- 2017-01-11 AU AU2017206718A patent/AU2017206718B2/en active Active
- 2017-01-11 EP EP17701409.9A patent/EP3402529A1/en active Pending
- 2017-01-11 CN CN201780016316.1A patent/CN108697807B/zh active Active
- 2017-01-11 CA CA3239447A patent/CA3239447A1/en active Pending
-
2018
- 2018-07-04 MX MX2023002076A patent/MX2023002076A/es unknown
-
2020
- 2020-05-07 US US16/868,693 patent/US11273142B2/en active Active
-
2021
- 2021-12-17 AU AU2021286420A patent/AU2021286420B2/en active Active
-
2022
- 2022-02-04 JP JP2022016251A patent/JP7640481B2/ja active Active
- 2022-03-14 US US17/693,478 patent/US20220280470A1/en active Pending
-
2024
- 2024-06-13 AU AU2024204027A patent/AU2024204027A1/en active Pending
-
2025
- 2025-02-20 JP JP2025025705A patent/JP2025071236A/ja active Pending